Effects of co-administration of arsenic trioxide and Schiff base oxovanadium complex on the induction of apoptosis in acute promyelocytic leukemia ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2021-07-13

AUTHORS

Sara Mirjalili, Ali Khaleghian, Fatemeh Kalalinia

ABSTRACT

Acute promyelocytic leukaemia (APL) is commonly treated with arsenic trioxide (As2O3) that has many side effects. Given the increasing trend of studies on beneficial therapeutic properties of synthetic compounds containing vanadium, the present study sought to use Schiff base oxovanadium complex to reduce the needed concentration of arsenic trioxide. The HL-60 cell line, which is a model of APL, was selected and the effects of arsenic trioxide and Schiff base oxovanadium complex were individually and simultaneously evaluated on the cell viability by the MTT assay. Flow cytometry and Real-time RT-PCR were also performed to investigate the rate of apoptosis and the expression of P53 and P21 genes, respectively. The IC50 of arsenic trioxide and Schiff base oxovanadium complex on Hl-60 cells was 8.37 ± 0.36 µM and 34.12 ± 1.52 µg/ml, respectively. At the simultaneous administration of both compounds, the maximum decrease in the cell viability was seen in co-administration of 40 µg/ml of Schiff base oxovanadium complex and 0.001 µM of arsenic trioxide. Real-time RT-PCR indicated that the co-administration of Schiff base oxovanadium complex 40 µg/ml and arsenic trioxide 0.001 µM could increase the expression of P53 and P21 genes by 3.76 ± 0.19 and 6.57 ± 1.29 fold change, respectively to the control sample. The flow cytometry studies also indicated that this co-administration could induce apoptosis up to 67% ± 0.9% significantly higher than the control sample. The use of Schiff base oxovanadium complex could significantly reduce the required dose of arsenic trioxide to induce apoptosis in HL-60 cells. More... »

PAGES

1067-1080

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10534-021-00330-z

DOI

http://dx.doi.org/10.1007/s10534-021-00330-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1139663067

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34255251


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arsenic Trioxide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arsenicals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Promyelocytic, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Schiff Bases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Biochemistry department, Faculty of Medicine, Semnan University of Medical Sciences, 5th Km Damghan Road, P.O. Box 3514533, Semnan, Iran", 
          "id": "http://www.grid.ac/institutes/grid.486769.2", 
          "name": [
            "Biochemistry department, Faculty of Medicine, Semnan University of Medical Sciences, 5th Km Damghan Road, P.O. Box 3514533, Semnan, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mirjalili", 
        "givenName": "Sara", 
        "id": "sg:person.07763547147.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07763547147.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Biochemistry department, Faculty of Medicine, Semnan University of Medical Sciences, 5th Km Damghan Road, P.O. Box 3514533, Semnan, Iran", 
          "id": "http://www.grid.ac/institutes/grid.486769.2", 
          "name": [
            "Biochemistry department, Faculty of Medicine, Semnan University of Medical Sciences, 5th Km Damghan Road, P.O. Box 3514533, Semnan, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khaleghian", 
        "givenName": "Ali", 
        "id": "sg:person.0601167472.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601167472.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dept. Pharmaceutical Biotechnology, School of Pharmacy, P. O. Box 91775-1365, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "Dept. Pharmaceutical Biotechnology, School of Pharmacy, P. O. Box 91775-1365, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalalinia", 
        "givenName": "Fatemeh", 
        "id": "sg:person.01354672317.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354672317.51"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.leu.2403923", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039139072", 
          "https://doi.org/10.1038/sj.leu.2403923"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11243-014-9798-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031731483", 
          "https://doi.org/10.1007/s11243-014-9798-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10895-018-2306-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107740655", 
          "https://doi.org/10.1007/s10895-018-2306-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11033-019-05098-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122015881", 
          "https://doi.org/10.1007/s11033-019-05098-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11010-009-0160-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023105611", 
          "https://doi.org/10.1007/s11010-009-0160-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12011-018-1540-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107768158", 
          "https://doi.org/10.1007/s12011-018-1540-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2011.450", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042124660", 
          "https://doi.org/10.1038/bjc.2011.450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1756-8722-3-28", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041035664", 
          "https://doi.org/10.1186/1756-8722-3-28"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-07-13", 
    "datePublishedReg": "2021-07-13", 
    "description": "Acute promyelocytic leukaemia (APL) is commonly treated with arsenic trioxide (As2O3) that has many side effects. Given the increasing trend of studies on beneficial therapeutic properties of synthetic compounds containing vanadium, the present study sought to use Schiff base oxovanadium complex to reduce the needed concentration of arsenic trioxide. The HL-60 cell line, which is a model of APL, was selected and the effects of arsenic trioxide and Schiff base oxovanadium complex were individually and simultaneously evaluated on the cell viability by the MTT assay. Flow cytometry and Real-time RT-PCR were also performed to investigate the rate of apoptosis and the expression of P53 and P21 genes, respectively. The IC50 of arsenic trioxide and Schiff base oxovanadium complex on Hl-60 cells was 8.37\u2009\u00b1\u20090.36\u00a0\u00b5M and 34.12\u2009\u00b1\u20091.52\u00a0\u00b5g/ml, respectively. At the simultaneous administration of both compounds, the maximum decrease in the cell viability was seen in co-administration of 40\u00a0\u00b5g/ml of Schiff base oxovanadium complex and 0.001\u00a0\u00b5M of arsenic trioxide. Real-time RT-PCR indicated that the co-administration of Schiff base oxovanadium complex 40\u00a0\u00b5g/ml and arsenic trioxide 0.001\u00a0\u00b5M could increase the expression of P53 and P21 genes by 3.76\u2009\u00b1\u20090.19 and 6.57\u2009\u00b1\u20091.29 fold change, respectively to the control sample. The flow cytometry studies also indicated that this co-administration could induce apoptosis up to 67%\u2009\u00b1\u20090.9% significantly higher than the control sample. The use of Schiff base oxovanadium complex could significantly reduce the required dose of arsenic trioxide to induce apoptosis in HL-60 cells.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10534-021-00330-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1102420", 
        "issn": [
          "0966-0844", 
          "1572-8773"
        ], 
        "name": "BioMetals", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "acute promyelocytic leukemia", 
      "expression of p53", 
      "real-time RT-PCR", 
      "arsenic trioxide", 
      "RT-PCR", 
      "HL-60 cells", 
      "acute promyelocytic leukemia cells", 
      "p21 gene", 
      "cell viability", 
      "flow cytometry studies", 
      "rate of apoptosis", 
      "simultaneous administration", 
      "promyelocytic leukemia", 
      "side effects", 
      "beneficial therapeutic properties", 
      "promyelocytic leukemia cells", 
      "induction of apoptosis", 
      "cytometry studies", 
      "leukemia cells", 
      "MTT assay", 
      "HL-60 cell line", 
      "cell lines", 
      "therapeutic properties", 
      "apoptosis", 
      "control samples", 
      "fold change", 
      "present study", 
      "p53", 
      "cells", 
      "maximum decrease", 
      "leukemia", 
      "synthetic compounds", 
      "expression", 
      "administration", 
      "dose", 
      "study", 
      "cytometry", 
      "viability", 
      "IC50", 
      "trioxide", 
      "effect", 
      "genes", 
      "induction", 
      "assays", 
      "samples", 
      "decrease", 
      "rate", 
      "concentration", 
      "changes", 
      "compounds", 
      "use", 
      "lines", 
      "complexes", 
      "trend of studies", 
      "trends", 
      "oxovanadium complexes", 
      "model", 
      "properties", 
      "vanadium"
    ], 
    "name": "Effects of co-administration of arsenic trioxide and Schiff base oxovanadium complex on the induction of apoptosis in acute promyelocytic leukemia cells", 
    "pagination": "1067-1080", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1139663067"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10534-021-00330-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34255251"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10534-021-00330-z", 
      "https://app.dimensions.ai/details/publication/pub.1139663067"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_913.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10534-021-00330-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10534-021-00330-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10534-021-00330-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10534-021-00330-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10534-021-00330-z'


 

This table displays all metadata directly associated to this object as RDF triples.

203 TRIPLES      22 PREDICATES      101 URIs      85 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10534-021-00330-z schema:about N00bcfd83d75b43e1afc250ef97f4f75c
2 N0d157a5edbaa4b11bdd6570547055492
3 N23da8828548642f2bc9b9fd448add980
4 N50f22d05a9944e11bb1ca39355dac6dc
5 N686a8aa25f3e414b9398e68c9d1beb95
6 N6f06afe83ff34fa38577bd1455e42c22
7 N97cdb36b30794caaa41f273105863b17
8 Ne8d6547fc36d4358a78b45c1ae2d2e58
9 anzsrc-for:11
10 anzsrc-for:1112
11 schema:author N5258611ac3a54ff4bf2c8ad6bc08b72d
12 schema:citation sg:pub.10.1007/s10895-018-2306-4
13 sg:pub.10.1007/s11010-009-0160-z
14 sg:pub.10.1007/s11033-019-05098-7
15 sg:pub.10.1007/s11243-014-9798-9
16 sg:pub.10.1007/s12011-018-1540-6
17 sg:pub.10.1038/bjc.2011.450
18 sg:pub.10.1038/sj.leu.2403923
19 sg:pub.10.1186/1756-8722-3-28
20 schema:datePublished 2021-07-13
21 schema:datePublishedReg 2021-07-13
22 schema:description Acute promyelocytic leukaemia (APL) is commonly treated with arsenic trioxide (As2O3) that has many side effects. Given the increasing trend of studies on beneficial therapeutic properties of synthetic compounds containing vanadium, the present study sought to use Schiff base oxovanadium complex to reduce the needed concentration of arsenic trioxide. The HL-60 cell line, which is a model of APL, was selected and the effects of arsenic trioxide and Schiff base oxovanadium complex were individually and simultaneously evaluated on the cell viability by the MTT assay. Flow cytometry and Real-time RT-PCR were also performed to investigate the rate of apoptosis and the expression of P53 and P21 genes, respectively. The IC50 of arsenic trioxide and Schiff base oxovanadium complex on Hl-60 cells was 8.37 ± 0.36 µM and 34.12 ± 1.52 µg/ml, respectively. At the simultaneous administration of both compounds, the maximum decrease in the cell viability was seen in co-administration of 40 µg/ml of Schiff base oxovanadium complex and 0.001 µM of arsenic trioxide. Real-time RT-PCR indicated that the co-administration of Schiff base oxovanadium complex 40 µg/ml and arsenic trioxide 0.001 µM could increase the expression of P53 and P21 genes by 3.76 ± 0.19 and 6.57 ± 1.29 fold change, respectively to the control sample. The flow cytometry studies also indicated that this co-administration could induce apoptosis up to 67% ± 0.9% significantly higher than the control sample. The use of Schiff base oxovanadium complex could significantly reduce the required dose of arsenic trioxide to induce apoptosis in HL-60 cells.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf N124a6c1915af4d3aa33d4231d70fbcbc
27 Nb9a5fb83b0504bb497d1cd5e14b3fd0d
28 sg:journal.1102420
29 schema:keywords HL-60 cell line
30 HL-60 cells
31 IC50
32 MTT assay
33 RT-PCR
34 acute promyelocytic leukemia
35 acute promyelocytic leukemia cells
36 administration
37 apoptosis
38 arsenic trioxide
39 assays
40 beneficial therapeutic properties
41 cell lines
42 cell viability
43 cells
44 changes
45 complexes
46 compounds
47 concentration
48 control samples
49 cytometry
50 cytometry studies
51 decrease
52 dose
53 effect
54 expression
55 expression of p53
56 flow cytometry studies
57 fold change
58 genes
59 induction
60 induction of apoptosis
61 leukemia
62 leukemia cells
63 lines
64 maximum decrease
65 model
66 oxovanadium complexes
67 p21 gene
68 p53
69 present study
70 promyelocytic leukemia
71 promyelocytic leukemia cells
72 properties
73 rate
74 rate of apoptosis
75 real-time RT-PCR
76 samples
77 side effects
78 simultaneous administration
79 study
80 synthetic compounds
81 therapeutic properties
82 trend of studies
83 trends
84 trioxide
85 use
86 vanadium
87 viability
88 schema:name Effects of co-administration of arsenic trioxide and Schiff base oxovanadium complex on the induction of apoptosis in acute promyelocytic leukemia cells
89 schema:pagination 1067-1080
90 schema:productId N835165de0021480391de0b0c7a9c6fd5
91 N940394e534ff4d06b6f851295caebe81
92 Nce29f993a4564072992e13652fa7f669
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1139663067
94 https://doi.org/10.1007/s10534-021-00330-z
95 schema:sdDatePublished 2022-05-10T10:29
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher N02081623ea7443a394191cf4d932ec81
98 schema:url https://doi.org/10.1007/s10534-021-00330-z
99 sgo:license sg:explorer/license/
100 sgo:sdDataset articles
101 rdf:type schema:ScholarlyArticle
102 N00bcfd83d75b43e1afc250ef97f4f75c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Leukemia, Promyelocytic, Acute
104 rdf:type schema:DefinedTerm
105 N02081623ea7443a394191cf4d932ec81 schema:name Springer Nature - SN SciGraph project
106 rdf:type schema:Organization
107 N0d157a5edbaa4b11bdd6570547055492 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Humans
109 rdf:type schema:DefinedTerm
110 N124a6c1915af4d3aa33d4231d70fbcbc schema:volumeNumber 34
111 rdf:type schema:PublicationVolume
112 N23da8828548642f2bc9b9fd448add980 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Schiff Bases
114 rdf:type schema:DefinedTerm
115 N30b81bafe4fd4ebf9f1ccfbbcb674779 rdf:first sg:person.01354672317.51
116 rdf:rest rdf:nil
117 N50f22d05a9944e11bb1ca39355dac6dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Oxides
119 rdf:type schema:DefinedTerm
120 N5258611ac3a54ff4bf2c8ad6bc08b72d rdf:first sg:person.07763547147.22
121 rdf:rest N6be943bb82824f84a0286f769a9c9652
122 N686a8aa25f3e414b9398e68c9d1beb95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Antineoplastic Agents
124 rdf:type schema:DefinedTerm
125 N6be943bb82824f84a0286f769a9c9652 rdf:first sg:person.0601167472.37
126 rdf:rest N30b81bafe4fd4ebf9f1ccfbbcb674779
127 N6f06afe83ff34fa38577bd1455e42c22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Apoptosis
129 rdf:type schema:DefinedTerm
130 N835165de0021480391de0b0c7a9c6fd5 schema:name dimensions_id
131 schema:value pub.1139663067
132 rdf:type schema:PropertyValue
133 N940394e534ff4d06b6f851295caebe81 schema:name pubmed_id
134 schema:value 34255251
135 rdf:type schema:PropertyValue
136 N97cdb36b30794caaa41f273105863b17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Arsenicals
138 rdf:type schema:DefinedTerm
139 Nb9a5fb83b0504bb497d1cd5e14b3fd0d schema:issueNumber 5
140 rdf:type schema:PublicationIssue
141 Nce29f993a4564072992e13652fa7f669 schema:name doi
142 schema:value 10.1007/s10534-021-00330-z
143 rdf:type schema:PropertyValue
144 Ne8d6547fc36d4358a78b45c1ae2d2e58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Arsenic Trioxide
146 rdf:type schema:DefinedTerm
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
151 schema:name Oncology and Carcinogenesis
152 rdf:type schema:DefinedTerm
153 sg:journal.1102420 schema:issn 0966-0844
154 1572-8773
155 schema:name BioMetals
156 schema:publisher Springer Nature
157 rdf:type schema:Periodical
158 sg:person.01354672317.51 schema:affiliation grid-institutes:None
159 schema:familyName Kalalinia
160 schema:givenName Fatemeh
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354672317.51
162 rdf:type schema:Person
163 sg:person.0601167472.37 schema:affiliation grid-institutes:grid.486769.2
164 schema:familyName Khaleghian
165 schema:givenName Ali
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601167472.37
167 rdf:type schema:Person
168 sg:person.07763547147.22 schema:affiliation grid-institutes:grid.486769.2
169 schema:familyName Mirjalili
170 schema:givenName Sara
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07763547147.22
172 rdf:type schema:Person
173 sg:pub.10.1007/s10895-018-2306-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107740655
174 https://doi.org/10.1007/s10895-018-2306-4
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/s11010-009-0160-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1023105611
177 https://doi.org/10.1007/s11010-009-0160-z
178 rdf:type schema:CreativeWork
179 sg:pub.10.1007/s11033-019-05098-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122015881
180 https://doi.org/10.1007/s11033-019-05098-7
181 rdf:type schema:CreativeWork
182 sg:pub.10.1007/s11243-014-9798-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031731483
183 https://doi.org/10.1007/s11243-014-9798-9
184 rdf:type schema:CreativeWork
185 sg:pub.10.1007/s12011-018-1540-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107768158
186 https://doi.org/10.1007/s12011-018-1540-6
187 rdf:type schema:CreativeWork
188 sg:pub.10.1038/bjc.2011.450 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042124660
189 https://doi.org/10.1038/bjc.2011.450
190 rdf:type schema:CreativeWork
191 sg:pub.10.1038/sj.leu.2403923 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039139072
192 https://doi.org/10.1038/sj.leu.2403923
193 rdf:type schema:CreativeWork
194 sg:pub.10.1186/1756-8722-3-28 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041035664
195 https://doi.org/10.1186/1756-8722-3-28
196 rdf:type schema:CreativeWork
197 grid-institutes:None schema:alternateName Dept. Pharmaceutical Biotechnology, School of Pharmacy, P. O. Box 91775-1365, Mashhad, Iran
198 schema:name Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
199 Dept. Pharmaceutical Biotechnology, School of Pharmacy, P. O. Box 91775-1365, Mashhad, Iran
200 rdf:type schema:Organization
201 grid-institutes:grid.486769.2 schema:alternateName Biochemistry department, Faculty of Medicine, Semnan University of Medical Sciences, 5th Km Damghan Road, P.O. Box 3514533, Semnan, Iran
202 schema:name Biochemistry department, Faculty of Medicine, Semnan University of Medical Sciences, 5th Km Damghan Road, P.O. Box 3514533, Semnan, Iran
203 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...